1. Home
  2. |Insights
  3. |Administration Boosts Clean Energy with $4 Billion Loan Guarantee Program

Administration Boosts Clean Energy with $4 Billion Loan Guarantee Program

Client Alert | 1 min read | 07.07.14

On July 3, the Department of Energy announced the issuance of Solicitation No. DE-SOL-0007154, "Loan Guarantee Solicitation for Applications for Renewable Energy Projects and Efficient Energy Projects," under which DOE will make up to $4 billion in loan guarantees available to entities developing renewable energy and energy efficiency projects and technologies in the U.S., the latest effort by the Obama Administration to stimulate investment in advanced energy technologies that reduce or avoid anthropogenic greenhouse gas emissions (discussed previously here and here). The new DOE offering is focused on providing loan guarantees to qualifying projects in "five key technology areas," including smart grid systems, clean power production with energy storage, biorefineries, advanced waste-to-energy conversion, and end-use efficiency improvements, among others, and joins two other DOE programs now accepting applications, the $8 billion Advanced Fossil Energy Projects solicitation and the $16 billion Advanced Technology Vehicle Manufacturing loan program.


Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...